Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally. The company provides discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also offers exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, as well as acute, sub-chronic, and chronic toxicity studies; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, biometrics and clinical data management, regulatory, medical monitoring, pharmacovigilance, and medical writing services. Further, it offers other drug modalities, which include peptides, oligonucleotide synthesis, antibody drug conjugate, PROTACs, and CAR T-cell therapy services. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Syngene International Limited

Athmic Biotech Solutions Pvt Ltd is involved in biological sample testing services and research consultancy in various fields such as Biotechnology, Biochemistry, Microbiology, and Molecular Biology, self-described.

Athmic Biotech Solutions Pvt Ltd

Reliance Life Sciences provides clinical research services, regenerative medicine, and specialty pharmaceuticals. Self-described as a global biopharmaceutical business based in India, it offers a complete range of services for clinical development of molecules and is involved in high-end DNA-based diagnostic testing.

Reliance Life Sciences

Syngene International Limited is an innovation-led contract research, development and manufacturing organization offering integrated scientific services from early discovery to commercial supply. It provides customized end-to-end solutions to fulfill R&D and manufacturing requirements.

Metric
Company Name	Syngene International Limited	Athmic Biotech Solutions Pvt Ltd	Reliance Life Sciences
Symbol	SYNGENE
MSH ID	COM:SYNGENEINTL	COM:ATHMICBIOTECH	COM:RELLIFE
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	IN	IN	IN
Stage
Employee Count	6.51K
Website	syngeneintl.com	athmicbiotech.com	rellife.com
LinkedIn
Founders

Metric
Market Cap	3.49B
Enterprise Value
Monthly Web Traffic		17.18K
Web Traffic Growth		0.08
Valuation
Raised Capital

Metric
Revenue	411.87M
Revenue (LTM)
Revenue (NTM)
Gross Profit	146.84M
EBITDA	126.35M
Operating Income	76.07M
Net Income	60.21M
EPS	0.15
Diluted EPS	0.15
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.71
Operating Profit Margin	0.20
EBITDA Margin	0.31
Net Profit Margin	0.15
Return on Equity	0.13
Return on Assets	0.09
Return on Capital Employed	0.14

COM:SYNGENEINTL

Syngene International Limited

Last Close

869.30

25/11 09:40

Market Cap

295.33B

Beta: -

Volume Today

420.79K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	59.46
P/B Ratio	7.64
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	10.85
EV Multiple	35.87

Metric
Days Sales Outstanding	46.41
Days Payables Outstanding	99.94
Days Inventory Outstanding	94.68
Operating Cycle	136.18
Cash Conversion Cycle	41.32
Asset Turnover	0.62

Metric
Operating Cash Flow	129.25M
Free Cash Flow	68.95M
Cash Flow to Debt	4.32
Operating Cash Flow/Sales	0.24
Free Cash Flow Yield

Metric
Cash & Equivalents	66.53M
Accounts Receivable	10.24M
Inventory	28.16M
Goodwill
Debt to Capitalization	0.08
Debt to Assets	0.14
Current Ratio	1.94
Quick Ratio	1.70

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue